Cardinal Health has completed the aquisition of the assets of Biotech, an operator of Positron Emission Tomography (PET) cyclotrons and nuclear pharmacies in the Southwestern US.
With the addition of Biotech’s four nuclear pharmacies, Cardinal Health will expand its existing US PET business. The facilities are located across Arizona, Nevada, New Mexico and Texas.
In addition to the manufacturing and distribution of fluorodeoxyglucose (FDG)-based PET agents, Cardinal Health recently opened its network to support clinical trials of new and novel PET agents to advance the future of molecular imaging.
John Rademacher, president and general manager of Nuclear and Specialty Pharmacy Services for Cardinal Health, said: “The Biotech acquisition helps demonstrate Cardinal Health’s commitment to advancing the future of molecular imaging, accelerates the build-out of our PET business and augments our network of nuclear pharmacies.